ClinicalTrials.gg
Active, not recruitingNCT06615505ASCENDUpdated Nov 2, 2026

ASCEND: A Clinical Trial to Evaluate the Safety and Effectiveness of VIA Disc NP, a Supplement for Degenerated Intervertebral Discs

An interventional study of VIA Disc NP and Sham Injection in Degenerative Disc Disease, Disc Degeneration and Lumbar Discogenic Pain, sponsored by VIVEX Biologics, Inc.. Active, not recruiting at 5 sites in Australia. Open to participants aged 22 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by VIVEX Biologics, Inc. · Not applicable, Interventional, and Other

How we know

Updated Nov 2, 2026Design changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
22 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Intervertebral Disc Degeneration with a site in Australia — 4 open to participants now, 5 under way, none of them phase 3. Intervertebral Disc Degeneration · Australia.

Enrollment
3rd of 12
121 · median 60
Started
2024
with 2 others
No phase
6 of 13
2 open now
Registered
12th of 13
by date
Lead sponsor
1 of 13
VIVEX Biologics, Inc.

Among the 13 studies in Intervertebral Disc Degeneration with a site in Australia, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2024, is one of 6 with no phase, and was the 12th registered.

Intervertebral Disc Degeneration

462 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.

Browse Intervertebral Disc Degeneration studies →

Open to participants now

4 of the 13 studies in Intervertebral Disc Degeneration with a site in Australia are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 60 Intervertebral Disc Degeneration studies recruiting now, 29 (48%) set no upper age limit and 16 (27%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 22 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Intervertebral Disc Degeneration with a site in Australia, or all of them as a file.
02

Study summary

VIA Disc NP is an off-the-shelf minimally processed human nucleus pulposus tissue allograft intended to supplement degenerated intervertebral discs.

The study is a randomized, double-blind, sham-controlled, multi-center study in participants with symptomatic lumbar intervertebral disc degeneration (> 6 months) and unresponsive to conservative therapy for at least 3 months. Participants will be randomized on a 1:1 basis to receive either a single VIA Disc NP intradiscal injection at 1 or 2 levels or a sham procedure at 1 or 2 levels.

Participants who consent to participate in the study and meet all eligibility criteria during the Screening/Baseline period will return on Day 1 to be randomized to either the VIA Disc NP or sham-control group. At 12-weeks post-treatment, participants allocated to the sham-control group will be given the option to crossover to the VIA Disc NP group if they meet the requirement to crossover.

All participants will be followed through 52-weeks post-treatment at which time they will be asked if they would like to consent to participate in an extended long-term follow-up period. The sham-control group participants who did not crossover at 12-weeks will be exited from the study at this visit. If participants consent to participate in the extended long-term follow-up period, the VIA Disc NP group will be followed through 24-Months and the sham-control group will be followed through 27-months. If the participant declines participation, they will be exited from the study at this visit.

03

Conditions studied

  • Degenerative Disc Disease
  • Disc Degeneration
  • Lumbar Discogenic Pain

Keywords

  • Degenerative Disc Disease
  • Lumbar Discogenic Pain
04

Who can participate

Ages eligible
22 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Age 22 to 85 years old
  2. Diagnosis of early to moderate DDD, Modified Pfirrmann Grade 3-7
  3. Chronic axial midline low-back pain with or without referred non-radicular leg pain for at least 6 months prior to screening; unresponsive to at least 3 months of conservative care
  4. Positive hip flexion test as confirmed with the Neurologic Exam indicating positive provocation with sustained hip flexion at the time of screening
  5. Demonstrated intolerance to sitting for more than 30 minutes at a time based on self-report or assessed by a qualified healthcare professional at the screening visit
  6. Low-back pain severity score of ≥ 40 to ≤ 90 mm on the VAS at the time of Screening
  7. ODI score of ≥ 40 to ≤ 80 at the time of Screening

Key Exclusion Criteria:

  1. to MRI for any reason
  2. Contraindications to the proposed sedation/anesthetic protocol
  3. Symptomatic involvement of more than two lumbar discs
  4. Fracture of the lumbar spine, previous lumbar spine surgery or previous treatment of the target disc(s)
  5. Grade 2 or higher spondylolisthesis at the target disc, lumbar spondylitis or other undifferentiated spondyloarthropathy, or Type III Modic changes around the target disc
  6. Clinical suspicion of a full thickness annular tear at the target disc or other abnormal disc morphology
  7. Clinical suspicion of facet pain as primary pain generator
  8. Women who are pregnant or breastfeeding at the time of enrollment and/or plan to become pregnant during the study. Pregnancy is confirmed by:

    • A positive pregnancy test during the screening visit
    • Self-reported pregnancy
  9. Women of (WOCBP) who are not using a reliable form of (as determined by the Investigator)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
121 participants (actual)

Study arms

  • Active comparator
    VIA Disc NP

    Other: VIA Disc NP

  • Sham comparator
    Sham Arm

    Other: Sham Injection

Interventions

  • OtherVIA Disc NP

    Participants will receive a single dose, intradiscal injection of 100 mg of VIA Disc NP mixed with sterile saline according to product Instructions for Use (IFU) and administered to the affected level(s), L1-S1 (1 or 2 levels).

  • OtherSham Injection

    Participants will receive the sham procedure at 1 or 2 levels. The procedure will be identical to the investigational procedure with the following exception: A 20G spinal needle will be carefully inserted through the skin and muscle of the back but WILL NOT penetrate the annulus fibrosus of the intervertebral disc.

06

What researchers measure

Primary outcomes

  1. Primary Effectiveness Endpoint - Proportion of participants achieving MCID in VAS score from Baseline to 26 weeks.

    A comparison of the proportion of participants who show a minimally clinically important difference (MCID), defined as at least a 30% reduction in back pain VAS score from baseline to 26 weeks (6 months), in the VIA Disc NP group to that in the sham-control group.

    Time frame: Baseline to 26 Weeks

  2. Primary Safety Endpoint - Proportion of participants reporting Treatment-related AEs at 12 weeks

    The proportion of participants that experience one or more treatment-related (including procedure) adverse events in the VIA Disc NP group compared to the sham-control group at 12 weeks (3 months) as determined by the Principal Investigator.

    Time frame: Baseline to 12 weeks

07

Study locations

5 sites
  • Genesis Research Services Pty Ltd
    Broadmeadow, New South Wales 2292, Australia
  • Australian Medical Research
    Hurstville, New South Wales 2220, Australia
  • Sydney Pain Research Centre
    Wahroonga, New South Wales 2076, Australia
  • Cercare Clinical Research
    Wayville, South Australia 5034, Australia
  • Monash House Research Centre Pty Ltd
    Clayton, Victoria 3168, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Feb 2026, 16 months.

Of 45 industry-sponsored interventional studies with no phase under Intervertebral Disc Degeneration, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 82. This study's 16 months is below that.

Counting every sponsor, half of 85 studies reached it within 50 months; a quarter within 27 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2024
First posted
Sep 26, 2024
StartActual
Oct 4, 2024
Primary completionActual
Feb 6, 2026
CompletionEst.
Nov 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Design
Phase 2→Not applicable
Nov 2, 2026
Show all 2 updates
  1. Nov 2, 2026
    Design Phase 2→Not applicable
    + 1 other change: identifiers
  2. Oct 5, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06615505
Lead sponsor
VIVEX Biologics, Inc.
Responsible party
Sponsor
First posted
Sep 26, 2024
Start date
Oct 4, 2024
Primary completion
Feb 6, 2026
Completion
Nov 2027 (estimated)
Last update
Nov 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion